Kahl, Brad S.

University of Wisconsin–Madison · Washington University in St. Louis

2 papers on CoChatORCID 0000-0003-0459-6609

Most cited papers

Verified
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 1,685
Verified
Prospective SPECT-CT organ dosimetry-driven radiation-absorbed dose escalation using the in-111 (111in)/yttrium 90 (90y) ibritumomab tiuxetan (Zevalin®) theranostic pair in patients with lymphoma at myeloablative dose levels
Wahl, R. L., Frey, E. C., Jacene, H. A., Kahl, B. S., Piantadosi, S., Bianco, J. A., Hammes, R. J., Jung, M., Kasecamp, W., He, B., et al. (2021) · Cancers
Radiopharmaceutical Chemistry and ApplicationsLymphoma Diagnosis and Treatment
Cited by 14

Go further with a free account

Verify every reference, keep papers in a library, and ask questions across them.

Sign up - it is free